Chevy Chase Trust’s Antares Pharma, Inc. ATRS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q2 | – | Sell |
-10,000
| Closed | -$41K | – | 654 |
|
|
2022
Q1 | $41K | Hold |
10,000
| – | – | ﹤0.01% | 643 |
|
|
2021
Q4 | $36K | Hold |
10,000
| – | – | ﹤0.01% | 669 |
|
|
2021
Q3 | $36K | Hold |
10,000
| – | – | ﹤0.01% | 661 |
|
|
2021
Q2 | $44K | Hold |
10,000
| – | – | ﹤0.01% | 676 |
|
|
2021
Q1 | $41K | Hold |
10,000
| – | – | ﹤0.01% | 676 |
|
|
2020
Q4 | $40K | Hold |
10,000
| – | – | ﹤0.01% | 651 |
|
|
2020
Q3 | $27K | Hold |
10,000
| – | – | ﹤0.01% | 639 |
|
|
2020
Q2 | $28K | Hold |
10,000
| – | – | ﹤0.01% | 641 |
|
|
2020
Q1 | $24K | Hold |
10,000
| – | – | ﹤0.01% | 629 |
|
|
2019
Q4 | $47K | Hold |
10,000
| – | – | ﹤0.01% | 836 |
|
|
2019
Q3 | $33K | Hold |
10,000
| – | – | ﹤0.01% | 644 |
|
|
2019
Q2 | $33K | Sell |
10,000
-5,000
| -33% | -$14.5K | ﹤0.01% | 647 |
|
|
2019
Q1 | $40K | Hold |
15,000
| – | – | ﹤0.01% | 654 |
|
|
2018
Q4 | $41K | Hold |
15,000
| – | – | ﹤0.01% | 697 |
|
|
2018
Q3 | $50K | Hold |
15,000
| – | – | ﹤0.01% | 658 |
|
|
2018
Q2 | $39K | Hold |
15,000
| – | – | ﹤0.01% | 669 |
|
|
2018
Q1 | $33K | Hold |
15,000
| – | – | ﹤0.01% | 656 |
|
|
2017
Q4 | $30K | Hold |
15,000
| – | – | ﹤0.01% | 671 |
|
|
2017
Q3 | $49K | Buy |
+15,000
| New | +$46.3K | ﹤0.01% | 663 |
|
Other funds holding ATRS
Chevy Chase Trust's ATRS Position: Q2 2022 in Review
Chevy Chase Trust sold out of Antares Pharma, Inc. (ATRS) in Q2 2022, closing a stake of 10,000 shares — an estimated $41K sold.
Chevy Chase Trust first reported a position in ATRS in Q3 2017 and held it in 19 quarters. The position peaked at $50K in Q3 2018. 1 fund tracked by Wall St. Rank holds ATRS as of Q2 2022.
- Chevy Chase Trust reported no remaining Antares Pharma, Inc. position as of Q2 2022 after selling out during the quarter.
- Chevy Chase Trust sold 10,000 Antares Pharma, Inc. shares in Q2 2022, an estimated $41K.
- Chevy Chase Trust first reported a position in Antares Pharma, Inc. in Q3 2017 and held it in 19 quarters.
- Chevy Chase Trust's Antares Pharma, Inc. position peaked at $50K in Q3 2018.
- 1 fund tracked by Wall St. Rank held Antares Pharma, Inc. as of Q2 2022.
Based on Chevy Chase Trust's 13F filing for Q2 2022, filed 10 Aug 2022.